ThioBridge™: Improved ADC Design & Delivery

Enhance your Antibody-Drug Conjugate (ADC) development with our ThioBridge™ conjugation platform technology.

Download Info Sheet

Overcome ADC development challenges with Abzena’s ThioBridge™ platform.

Linker technologies are a critical component in the development of antibody-drug conjugates (ADCs). Many linkers, particularly those used in first-generation ADC bioconjugation have limitations that can impact the safety and efficacy of the ADC. ThioBridge™ has been developed by Abzena to overcome the limitations associated with traditional linker technologies. ThioBridge™ leverages our deep understanding and expertise in conjugation chemistry.

Contact Us

ThioBridge™ is important for the advancement of ADCs. ThioBridge™ provides several benefits for ADC development as it addresses issues commonly associated with traditional bioconjugation technologies by:

  • Creating a very stable and uniform DAR composition
  • Improving manufacturing efficiency through a high-yielding ADC platform with up to 80% single DAR species
  • Exhibiting a high degree of stability in serum and being less prone to losing its payload in the body before it gets to its target
  • Allowing for an extensive range of linker designs to optimize the stability, loading and function of the payload
  • Providing versatility in the range of different payloads with different functions that can be attached to antibodies
The Abzena ADC Toolbox

Overcoming ADC challenges with ThioBridge™

Developed by our scientific experts, Abzena’s ThioBridge™ Antibody Drug Conjugation (ADC) platform is a solution that leverages 20+ years of our experience and data to address some of the challenges and learn from early successes that we have seen in ADC development. Fundamentally, ThioBridge™ conjugation overcomes many of the issues seen in existing technologies to give our customers ADCs improved stability, potency, and efficacy.

View ADC Toolbox Contact Us

ThioBridge™ Info Sheet: Linking Antibody to Drug

ThioBridge™: Improved ADC Design & Delivery - Abzena

While ADCs are a powerful and targeted approach to therapeutics, first-generation conjugation technologies have limitations such as inconsistent drug-to-antibody ratios (DAR) and the risk of early payload detachment.

Abzena’s ThioBridge™ conjugation technology offers a solution by providing a more uniform DAR profile, stable linker attachment, and improved pharmacokinetic properties.

Download Info Sheet

ThioBridge™ Conjugates Case Study

Bioconjugate Development

Download our case study today and learn more about how our ThioBridge™ technology. Discover how ThioBridge™ can improve the potency, efficacy, and stability of your ADC program as it bridges from preclinical into the clinic and beyond.

Discover Case Study

Moving ADCs forward with ThioBridge™

If you are looking to rapidly move your ADC program to its next regulatory or clinical milestone, contact us today and learn more about our ThioBridge® technology and how we can support you and your ADC development program.

Contact Us

Featured News & Insights

News

Abzena Announces Major Investment in Bioconjugation and ADC Capabilities

Read More

Blog

Blog: 10 Things to Consider When Developing an ADC

Read More

Blog

Essential Insights into Linker Chemistry for Antibody Drug Conjugates (ADCs)

Read More